In one paragraphArticle in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
6 authors at 3 institutions in 1 country.
Joseph ClaytonDepartment of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, MD 21201, United States.ORCID 0000-0002-2652-5994 Aarion RomanyDepartment of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, MD 21201, United States.ORCID 0000-0001-5439-8235 Evangelia MatenoglouDepartment of Biochemistry, Department of Medicine, Department of Oncology, Montefiore Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine, New York, NY 10461, United States.ORCID 0000-0001-9731-6703 Evripidis GavathiotisDepartment of Biochemistry, Department of Medicine, Department of Oncology, Montefiore Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine, New York, NY 10461, United States.ORCID 0000-0001-6319-8331 Poulikos I PoulikakosDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, United States.ORCID 0000-0001-6071-9963 Jana ShenDepartment of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, MD 21201, United States.ORCID 0000-0002-3234-0769 University of Maryland, Baltimore · USAlbert Einstein College of Medicine · USIcahn School of Medicine at Mount Sinai · US
Funding
Allosteric inhibitors targeting oncogenic BRAF V600E dimersR01CA238229 · NCI · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI GAVATHIOTIS, EVRIPIDIS · 2020 to 2024
$2.2MMechanisms determining tumor-selective potency of RAS pathway inhibitorsR01CA285713 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Poulikos I Poulikakos · 2024 to 2026
$2.1MREGULATION AND ADAPTIVE MECHANISMS OF ONCOGENIC RAS/ERK SIGNALINGR01CA240362 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI POULIKAKOS, POULIKOS I · 2020 to 2024
$2.0MA Multi-pronged Computational Approach to Advance Kinase Drug DiscoveryR01CA256557 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI SHEN, JANA · 2021 to 2024
$1.4MNCI NIH HHS R01 CA238229NCI NIH HHS R01 CA240362NCI NIH HHS R01 CA256557NCI NIH HHS R01 CA285713
6 · The paper itselfAbstract
Aberrant signaling of BRAF
Identifiers
PMID38168366
PMCPMC10760002
OpenAlexW4389640715
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390